REQUEST A DEMO
Total
USD $0.00
Search more companies

SL Therapeutics, Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: SL Therapeutics, Inc. Profile Updated: July 28, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

SL Therapeutics, Inc. is based in South Korea, with the head office in Seoul. The enterprise operates in the Research and Development in Nanotechnology industry. SL Therapeutics, Inc. was incorporated on April 10, 2026. SL Therapeutics, Inc. currently employs 6 (2023) people. There was a net sales revenue increase of 89.66% reported in SL Therapeutics, Inc.’s latest financial highlights for 2023. Over the same period, its total assets decreased by 34.82%. In 2023, SL Therapeutics, Inc.’s net profit margin increased by 845.85%.

Headquarters
711 Techno Complex Of Korea University 145 Anam-Dong, Sungbuk-Gu, Seoul 136-701, Korea
Seoul; Seoul;

Contact Details: Purchase the SL Therapeutics, Inc. report to view the information.

Website: http://www.stemlab.co.kr

Basic Information
Total Employees:
Purchase the SL Therapeutics, Inc. report to view the information.
Outstanding Shares:
Purchase the SL Therapeutics, Inc. report to view the information.
Financial Auditors:
Purchase the SL Therapeutics, Inc. report to view the information.
Incorporation Date:
April 10, 2026
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜스템랩
Company Performance
Financial values in the chart are available after SL Therapeutics, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
89.66%
Total Operating Revenue
-43.76%
Operating Profit
57.51%
EBITDA
34.31%
Net Profit/Loss for the Period
62.52%
Total Assets
-34.82%
Total Equity
-18.67%
Operating Profit Margin
667.47%
Net Profit Margin
845.85%
Return on Equity (ROE)
-152.03%
Debt / Equity
20070%
Quick Ratio
-80.12%
Cash Ratio
-0.09%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?